Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

VRTX vs MAIA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VRTX Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

VRTX Overall Winner 6-Pillar Tally: VRTX 5 – 1 MAIA Matrix Metrics: VRTX 8 – 2 MAIA

As of Nov 20, 2026, Vertex Pharmaceuticals Inc (VRTX) is the stronger overall head-to-head candidate over MAIA Biotechnology, Inc. (MAIA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). VRTX carries a Unified Composite Score of 40.9/100 (SELL) at $515.02 (25.9x Forward P/E, 37.8% operating margin), whereas MAIA carries 37.6/100 (SELL) at $1.11 (1.2x Forward P/E, 0.0% operating margin).

  • Defensive Composite Rating Caution: Although VRTX compares more favorably head-to-head, both VRTX (40.9/100 SELL) and MAIA (37.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: VRTX is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 40.9); meanwhile MAIA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VRTX vs MAIA
VRTX NASDAQ Head-to-Head Winner
Vertex Pharmaceuticals Inc
Pharmaceutical Preparations
$515.02
-1.08% 1D
Market Cap $132.0B
TTM Revenue $13.0B
Forward P/E 25.9x
Beta / 30D Vol 0.35β · 28% Vol
Unified Composite Score
40.9 / 100 SELL
Tech 25.0 Fund 47.0 Flow 69.0 Mom 46.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope 0.0%) with fading momentum, RSI 41
RSI-14: 40.9 · SMA20: $538.04 · SMA50: $522.73
MAIA NYSE American
MAIA Biotechnology, Inc.
Pharmaceutical Preparations
$1.11
-2.63% 1D
Market Cap $68.5M
TTM Revenue N/A
Forward P/E 1.2x
Beta / 30D Vol 1.65β · 108% Vol
Unified Composite Score
37.6 / 100 SELL
Tech 40.0 Fund 38.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 48.8 · SMA20: $1.11 · SMA50: $1.17

6-Pillar Scorecard Institutional Category Breakdown (VRTX 5 – 1 MAIA)

Columns: Metric · VRTX · MAIA
1. Valuation Multiples MAIA
Forward P/E 25.9x 1.2x
Trailing P/E 33.5x 1.2x
PEG Ratio 2.34x N/M
EV / Revenue 10.3x N/M
2. Growth & Scale VRTX
Revenue Growth (YoY) +11.8% +0.0%
Earnings Growth (YoY) -39.0% +0.0%
TTM Revenue (USD) $13.0B N/A
Market Cap $132.0B $68.5M
3. Profitability & Quality VRTX
Gross Margin 54.8% N/A
Operating Margin 37.8% 0.0%
Net Profit Margin 30.7% 0.0%
Return on Equity (ROE) 20.8% -341.5%
4. Balance Sheet & Cash Flow VRTX
Cash Generation (TTM) $3.20B -$20M
Cash Flow Margin 24.7% N/A
Net Cash / Leverage $1.50B Net Debt (0.31x D/E) $0.24 Book/Sh · -341.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VRTX
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 115.6% (33rd %ile) N/A (N/A)
Put/Call OI Skew 1.00x (Balanced) N/A
OBV Trend / Tech Phase DISTRIBUTION · Distribution NEUTRAL · Neutral
6. R&D & Supply-Chain Moat VRTX
OpEx & R&D Intensity 17.0% of Rev ($2.20B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VRTX (8) vs MAIA (2)
Institutional Metric VRTX MAIA Criterion Row Edge
Market Capitalization
Scale
$132.0B $68.5M Larger Scale VRTX
Trailing P/E Ratio
Valuation
33.5x 1.2x Lower Multiple MAIA
Forward P/E Ratio
Valuation
25.9x 1.2x Lower Multiple MAIA
Revenue Growth (YoY)
Growth
+11.8% +0.0% Higher Growth VRTX
Operating Margin (TTM)
Profitability
37.8% 0.0% Higher Margin VRTX
Net Profit Margin
Profitability
30.7% 0.0% Higher Margin VRTX
Return on Equity (ROE)
Capital Efficiency
20.8% -341.5% Higher ROE VRTX
52-Week Range Position
Momentum
66% ($412–$569) 10% ($1–$3) Stronger Trend VRTX
Beta / 30D Volatility
Risk Regime
0.35β · 28% Vol 1.65β · 108% Vol Lower Realized Risk VRTX
Unified Institutional Score
Composite Signal
40.9 / 100 (SELL) 37.6 / 100 (SELL) Higher Composite VRTX
Trailing 12M Revenue (USD)
Operating Scale
$13.0B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
54.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.34x PEG · 10.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$3.20B ($1.50B Net Debt (0.31x D/E)) -$20M ($0.24 Book/Sh · -341.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MAIA +2.0 pp
VRTX: -3.77% · MAIA: -1.77%
3M Horizon VRTX +11.83 pp
VRTX: -5.95% · MAIA: -17.78%
6M Horizon VRTX +31.81 pp
VRTX: +18.53% · MAIA: -13.28%
1Y Horizon VRTX +1.67 pp
VRTX: +22.32% · MAIA: +20.65%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VRTX vs MAIA. Trailing 12-month operating profitability (VRTX 37.8% vs MAIA 0.0%) and valuation multiples (VRTX 25.9x vs MAIA 1.2x Forward P/E) are benchmarked directly in Pillar 4 below.

VRTX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13.0B
Gross Margin54.8%
Op. Margin37.8%
ROE / Fwd P/E20.8% · 25.9x
MAIA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-341.5% · 1.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VRTX CONSOLIDATION
62d in phase · OBV DISTRIBUTION
Current IV 115.6%
IV Percentile 33rd %ile
Put/Call OI Skew 1.00x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact VRTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MAIA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MAIA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $537.79 · IV 35.9%

VRTX Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($53,779)

Compare $53,779 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 35.9% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $540 / $570 Bull Call Spread

Buy 1x $540C · Sell 1x $570C · 31d

Net Entry $1,114 Debit
T+5d @ +5% Move +$591 (+53%)
Max Risk / Buffer $1,114 Capped
5d Edge & Liquidity 0.9x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $500 / $470 Bull Put Spread

Sell 1x $500P · Buy 1x $470P · 31d

Net Entry $545 Credit
Max Credit / Yield +$545 (+22.2% RoM)
Max Risk / Buffer -8.0% Cushion ($2,455 Mgn)
5d Edge & Liquidity 77% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq B

Dec 18 $500P / $540-$580C Seagull

Sell 1x $500P · Buy 1x $540/$580C · 31d

Net Entry $240 Debit
T+5d @ +5% Move +$1,315 (+16.2% RoM)
Max Risk / Buffer -7.0% Put Cushion ($8,097 Mgn)
5d Edge & Liquidity 0.8x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VRTX Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $132.0B market capitalization and 37.8% operating margin.
OpEx & R&D Reinvestment 17.0% of Rev ($2.20B)
90D Engineering Disclosures 0 Published
MAIA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $68.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VRTX vs MAIA Key Questions & Quantitative Answers

As of Nov 20, 2026, Vertex Pharmaceuticals Inc (VRTX) is the stronger overall head-to-head candidate over MAIA Biotechnology, Inc. (MAIA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). VRTX carries a Unified Composite Score of 40.9/100 (SELL) at $515.02 (25.9x Forward P/E, 37.8% operating margin), whereas MAIA carries 37.6/100 (SELL) at $1.11 (1.2x Forward P/E, 0.0% operating margin). Defensive Composite Rating Caution: Although VRTX compares more favorably head-to-head, both VRTX (40.9/100 SELL) and MAIA (37.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: VRTX is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 40.9); meanwhile MAIA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VRTX leads the Growth & Scale pillar: VRTX posts +11.8% YoY revenue growth and -39.0% YoY earnings growth on $13.0B TTM revenue (54.8% gross margin, 37.8% operating margin), compared with MAIA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, VRTX generates $13.0B in USD-normalized revenue versus N/A for MAIA. In operating R&D and SG&A reinvestment, VRTX deploys 17.0% of Rev ($2.20B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MAIA.

MAIA screens cheaper on headline valuation multiples. VRTX trades at 25.9x Forward P/E, 33.5x Trailing P/E, 2.34x PEG, and 10.3x EV/Revenue (24.7% FCF margin), whereas MAIA trades at 1.2x Forward P/E, 1.2x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VRTX (20.8% ROE) versus MAIA (-341.5% ROE) capital efficiency.

In options market volatility and institutional positioning, VRTX carries 115.6% implied volatility (33rd %ile, Balanced (25th–60th %ile)), a 1.00x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.35β · 28% Vol realized risk). By comparison, MAIA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.65β · 108% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.